Biocon Limited announced its inclusion in S&P's Sustainability Yearbook 2024 for the second consecutive year, based on the S&P Global Corporate Sustainability Assessment (CSA) of Biocon and Biocon Biologics Limited for 2023.

Sustainability is integral to Biocon's business purpose, and the Group is executing a progressive Environment, Social and Governance (ESG) strategy aligned with stakeholder expectations and business objectives. Biocon's S&P Global ESG score was 63 versus 52 previously, placing it among the Top 10 global biotechnology companies from within the 300 companies that were assessed.

Kiran Mazumdar Shaw, Chairperson, Biocon & Biocon Biologics, said: "We are pleased to be recognized by S&P Global for our robust sustainable business practices. As a responsible corporate citizen, we are implementing a comprehensive ESG strategy across Biocon Group in line with our philosophy of Unconditional Equity. We are continuously striving to enable Patient Equity, People Equity, Environmental Equity, Stakeholder Equity and Social Equity."

The S&P Global CSA, a leading corporate sustainability database, enables companies to directly report key sustainability metrics and benchmark their sustainability performance on a wide range of industry-specific economic, environmental, and social criteria. The CSA score shows how a company compares with its peers and members of the prestigious Dow Jones Sustainability Indices (DJSI).